Your session is about to expire
← Back to Search
Corticosteroid
TRS01 for Anterior Uveitis
Phase 3
Waitlist Available
Research Sponsored by Tarsier Pharma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 days
Awards & highlights
Study Summary
This trial is testing a new eye drop for people with active non-infectious anterior uveitis, with or without uveitic glaucoma.
Eligible Conditions
- Anterior Uveitis
- Uveitic Glaucoma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 28 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Anterior Chamber Cell (ACC) grade on Day 28
Secondary outcome measures
Anterior Chamber Cell (ACC) grade on Day 21
Change from baseline (Day 1) in ACC Grade on Day 28 in the study eye
Change from baseline in ACC Grade on Day 21.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: TRS01Experimental Treatment1 Intervention
Group II: Active comparatorActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
TRS01
2021
Completed Phase 3
~150
Find a Location
Who is running the clinical trial?
Tarsier PharmaLead Sponsor
2 Previous Clinical Trials
53 Total Patients Enrolled
Lexitas Clinical TrialsStudy DirectorLexitas
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is this a popular study that many clinics are running in the city?
"There are 20 total sites for this trial, including Aurora, Colorado; Waltham, Massachusetts; and Norfolk, Virginia."
Answered by AI
Will this trial be open to recruitment of young adults?
"The age limit for enrolment in this clinical trial is 75 years old. There is no minimum age."
Answered by AI
Does TRS01 have the blessing of the FDA?
"TRS01 has received a 3 from our team at Power. This is because it is a Phase 3 trial, signifying that while there is data supporting efficacy, there are also multiple rounds of data that support safety."
Answered by AI
Who else is applying?
What state do they live in?
Texas
What site did they apply to?
Los Angeles 2
Austin
What portion of applicants met pre-screening criteria?
Met criteria
Why did patients apply to this trial?
Pressure goes up with steroids.
PatientReceived 2+ prior treatments
Share this study with friends
Copy Link
Messenger